{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T16:05:57Z","timestamp":1778256357041,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.ygyno.2009.10.076","type":"journal-article","created":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T09:16:05Z","timestamp":1263633365000},"page":"157-162","source":"Crossref","is-referenced-by-count":42,"title":["Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL\/0074)"],"prefix":"10.1016","volume":"116","author":[{"given":"Patricia","family":"Pautier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fumoleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Ringeisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie Tisseron","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lhomm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.10.076_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.10.076_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.10.076_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"suppl 2","key":"10.1016\/j.ygyno.2009.10.076_bib4","first-page":"S120","article-title":"A meta-analysis of the role of platinum compounds in advanced ovarian carcinoma","volume":"19","author":"Williams","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments","volume":"98","author":"Kyrgiou","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.10.076_bib6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000108591","article-title":"Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data","volume":"71","author":"Markman","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2009.10.076_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Bukowski","year":"2007","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib10","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2009.10.076_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.bjc.6601550","article-title":"Gefitinib and new epidermal growth factor receptor inhibitors","volume":"90","author":"Blackledge","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.10.076_bib12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.10.076_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib14","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by gefitinib, an epidermal growth factor receptor-selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.10.076_bib15","first-page":"4885","article-title":"Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of gefitinib (Iressa), an inhibitor of EGFR tyrosine kinase","volume":"6","author":"Sirotnak","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.10.076_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-007-0572-y","article-title":"In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines","volume":"62","author":"Smith","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solide tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.10.076_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.10.076_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for Phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2009.10.076_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Non-parametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"Suppl 4","key":"10.1016\/j.ygyno.2009.10.076_bib21","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.10.076_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.1992.10.4.529","article-title":"Significance of epidermal growth factor receptor in advanced ovarian cancer","volume":"10","author":"Scambia","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib24","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2003.12.008","article-title":"Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer","volume":"21","author":"Miller","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib25","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.10.076_bib26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","article-title":"A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer","volume":"109","author":"Posadas","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.10.076_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2006.10.053","article-title":"AGO ovarian cancer study group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy\u2014a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)","volume":"105","author":"Wagner","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib28","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2009.10.076_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJM200502243520825","article-title":"APL during gefitinib treatment for non-small-cell lung cancer","volume":"352","author":"Uchida","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.10.076_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajh.20569","article-title":"Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution","volume":"81","author":"Matsuo","year":"2006","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.10.076_bib32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.076_bib33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ijc.21460","article-title":"Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations","volume":"118","author":"Lacroix","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.10.076_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2009.10.076_bib35","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.bjc.6604371","article-title":"Scottish Gynaecological Cancer Trials. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers","volume":"98","author":"Vasey","year":"2008","journal-title":"Br. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809009032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809009032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T05:36:43Z","timestamp":1558762603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809009032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0090825809009032"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.10.076","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}